» Articles » PMID: 20976224

Risk Factors and Immunity in a Nationally Representative Population Following the 2009 Influenza A(H1N1) Pandemic

Overview
Journal PLoS One
Date 2010 Oct 27
PMID 20976224
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Understanding immunity, incidence and risk factors of the 2009 influenza A(H1N1) pandemic (2009 H1N1) through a national seroprevalence study is necessary for informing public health interventions and disease modelling.

Methods And Findings: We collected 1687 serum samples and individual risk factor data between November-2009 to March-2010, three months after the end of the 2009 H1N1 wave in New Zealand. Participants were randomly sampled from selected general practices countrywide and hospitals in the Auckland region. Baseline immunity was measured from 521 sera collected during 2004 to April-2009. Haemagglutination inhibition (HI) antibody titres of ≥1:40 against 2009 H1N1 were considered seroprotective as well as seropositive. The overall community seroprevalence was 26.7% (CI:22.6-29.4). The seroprevalence varied across age and ethnicity. Children aged 5-19 years had the highest seroprevalence (46.7%;CI:38.3-55.0), a significant increase from the baseline (14%;CI:7.2-20.8). Older adults aged ≥60 had no significant difference in seroprevalence between the serosurvey (24.8%;CI:18.7-30.9) and baseline (22.6%;CI:15.3-30.0). Pacific peoples had the highest seroprevalence (49.5%;CI:35.1-64.0). There was no significant difference in seroprevalence between both primary (29.6%;CI:22.6-36.5) and secondary healthcare workers (25.3%;CI:20.8-29.8) and community participants. No significant regional variation was observed. Multivariate analysis indicated age as the most important risk factor followed by ethnicity. Previous seasonal influenza vaccination was associated with higher HI titres. Approximately 45.2% of seropositive individuals reported no symptoms.

Conclusions: Based on age and ethnicity standardisation to the New Zealand Population, about 29.5% of New Zealanders had antibody titers at a level consistent with immunity to 2009 H1N1. Around 18.3% of New Zealanders were infected with the virus during the first wave including about one child in every three. Older people were protected due to pre-existing immunity. Age was the most important factor associated with infection followed by ethnicity. Healthcare workers did not appear to have an increased risk of infection compared with the general population.

Citing Articles

Baseline innate and T cell populations are correlates of protection against symptomatic influenza virus infection independent of serology.

Mettelman R, Souquette A, Van de Velde L, Vegesana K, Allen E, Kackos C Nat Immunol. 2023; 24(9):1511-1526.

PMID: 37592015 PMC: 10566627. DOI: 10.1038/s41590-023-01590-2.


Occupational risks for infection with influenza A and B: a national case-control study covering 1 July 2006-31 December 2019.

Toren K, Albin M, Bergstrom T, Alderling M, Schioler L, Aberg M Occup Environ Med. 2023; 80(7):377-383.

PMID: 37193595 PMC: 10314001. DOI: 10.1136/oemed-2022-108755.


The association between socioeconomic status and pandemic influenza: Systematic review and meta-analysis.

Mamelund S, Shelley-Egan C, Rogeberg O PLoS One. 2021; 16(9):e0244346.

PMID: 34492018 PMC: 8423272. DOI: 10.1371/journal.pone.0244346.


Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco using electronic health records.

Routledge I, Epstein A, Takahashi S, Janson O, Hakim J, Duarte E Nat Commun. 2021; 12(1):3566.

PMID: 34117227 PMC: 8195995. DOI: 10.1038/s41467-021-23651-6.


Citywide serosurveillance of the initial SARS-CoV-2 outbreak in San Francisco.

Routledge I, Epstein A, Takahashi S, Janson O, Hakim J, Duarte E Res Sq. 2021; .

PMID: 33564754 PMC: 7872360. DOI: 10.21203/rs.3.rs-180966/v1.


References
1.
Paine S, Mercer G, Kelly P, Bandaranayake D, Baker M, Huang Q . Transmissibility of 2009 pandemic influenza A(H1N1) in New Zealand: effective reproduction number and influence of age, ethnicity and importations. Euro Surveill. 2010; 15(24). View

2.
. Update: swine influenza A (H1N1) infections--California and Texas, April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(16):435-7. View

3.
Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M . Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010; 375(9720):1100-8. DOI: 10.1016/S0140-6736(09)62126-7. View

4.
La Ruche G, Tarantola A, Barboza P, Vaillant L, Gueguen J, Gastellu-Etchegorry M . The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. Euro Surveill. 2009; 14(42). DOI: 10.2807/ese.14.42.19366-en. View

5.
POTTER C, Jennings R, Nicholson K, Tyrrell D, Dickinson K . Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond). 1977; 79(3):321-32. PMC: 2129958. DOI: 10.1017/s0022172400053158. View